Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

predisposition to future cancers. This study tests a new drug combination for the treatment of hairy cell leukemia. The treatment involves 8 weeks of treatment with an oral drug called vemurafenib and 8 doses of

  • 0 views
  • 05 Jun, 2022
  • 1 location
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COWBOY)

immunotherapies targeted therapies (BRAF or MEK inhibitors), can induce faster and higher response rates, but often of shorter duration, even when combined. Initial attempts of combining vemurafenib or

  • 33 views
  • 24 Feb, 2022
  • 10 locations
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to

  • 0 views
  • 08 Jul, 2021
  • 1 location
  • 0 views
  • 05 Jul, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if treatment

  • 0 views
  • 27 Jul, 2022
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

corticosteroids
cellular therapy
solid tumour
MRI
solid tumor
  • 1032 views
  • 19 Sep, 2022
  • 107 locations
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine

absolute neutrophil count
external beam radiation therapy
neutrophil count
cancer
carcinoma
  • 0 views
  • 17 Mar, 2022
  • 7 locations
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS G12D mutated pancreatic cancer who have progressed on

KRAS
BRAF
cancer chemotherapy
  • 0 views
  • 12 Nov, 2021
  • 1 location
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of

  • 202 views
  • 09 Aug, 2022
  • 71 locations
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical

platelet count
neutrophil count
cancer
measurable disease
liver metastasis
  • 13 views
  • 06 Nov, 2021
  • 1 location